Loading...
OTCM
INFIQ
Market cap90kUSD
Oct 30, Last price  
0.00USD
Name

Infinity Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:INFIQ chart
P/E
—
P/S
0.04
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.04%
Rev. gr., 5y
-15.45%
Revenues
3m
+39.56%
49,826,59251,564,04834,836,97718,494,55824,536,35083,440,66649,538,71471,330,98792,773,16247,114,0000164,995,000109,066,00018,723,0006,000,00022,146,0003,049,0001,719,0001,858,0002,593,000
Net income
-43m
L-4.81%
1,058,9133,902,772-14,164,737-28,447,973-16,897,88723,654,357-32,505,265-48,983,659-40,042,101-53,964,000-126,780,000-17,416,000-128,376,000-30,101,000-41,830,000-11,253,000-47,057,000-42,937,000-45,442,000-43,256,000
CFO
-42m
L+4.46%
8,127,3864,749,9746,056,5759,655,70712,082,295-10,422,417-4,756,922-26,585,050-33,108,955-80,135,000-113,907,000117,715,000-83,653,000-154,356,000-36,711,000-4,714,000-41,530,000-35,739,000-40,618,000-42,431,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
URL
https://www.infi.com/
IPO date
Jul 27, 2000
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT